Physician profile
Cho May
NPI 1063805331
$1,205.67
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $473 · 2021: $289 · 2022: $134.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $209.32 | 2019-2022 | |
| Abbvie INC. | $159.01 | 2020-2022 | |
| Amarin Pharma, INC. | $148.40 | 2020 | |
| Allergan, INC. | $141.41 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $136.05 | 2019-2021 | |
| Gilead Sciences, INC. | $124.04 | 2019 | |
| Pfizer INC. | $116.79 | 2019 | |
| Glaxosmithkline, LLC. | $75.78 | 2022 | |
| Lilly USA, LLC | $42.09 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.43 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2020 | |
| Novo Nordisk INC | $11.77 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cho May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.